Tolerability of Linezolid in Individualized Chemotherapy Regimens for Adolescents with Multi- or Pre-Extensively Drug-Resistant Tuberculosis
Open Access
- 12 October 2025
- journal article
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 70 (5-6) , 21-26
Abstract
Background. The effectiveness of treatment for multidrug-resistant (MDR)/pre-extensively drug-resistant (pre-XDR) TB directly depends on the tolerability of chemotherapy, including linezolid, a group A drug. Aim: To study the incidence and types of adverse drug reactions (ADRs) to linezolid and ways to improve them in adolescents with MDR/pre-XDR TB. Methods. A retrospective study included 38 patients aged 13–17 years with various forms of pulmonary TB: MDR TB — 52.6 %, pre-XDR TB — 42.1 %, XDR TB — 5.3 %. The levels of eosinophils, hemoglobin, erythrocytes, leukocytes; ALT, AST were assessed. The immunological study (lymphocyte blast-transformation reaction) was performed to evaluate linezolid tolerability. ADRs were assessed by type (allergic, toxic, toxicoallergic) and severity. Results. The development of ADRs to linezolid was registered in 34.2 % of cases with prevailing toxic reactions (76.9 %). The most frequent reaction was anemia (46.2 %), ADRs of severity levels 1–2 were registered in 80 % of cases. ADRs were immunologically confirmed in 30.8 % of thecases — in patients with allergic, as well as both toxic and allergic reactions. In 84.6% of cases, short-term withdrawal of linezolid and symptomatic treatment were required. Conclusion. Despite the high frequency of ADRs induced by linezolid administration, most of them were mild and could be corrected without long-term drug withdrawal.Keywords
This publication has 14 references indexed in Scilit:
- Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis TreatmentClinical Infectious Diseases, 2022
- Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant TuberculosisClinical Infectious Diseases, 2021
- Safety of longer linezolid regimen in children with drug-resistant tuberculosis and extensive tuberculosis in Southwest ChinaJournal of Global Antimicrobial Resistance, 2020
- Linezolid-containing Treatment Regimens for Tuberculosis in ChildrenThe Pediatric Infectious Disease Journal, 2019
- New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based RecommendationsAmerican Journal of Respiratory and Critical Care Medicine, 2017
- The severity of peripheral blood eosinophilia indicates an eosinophilia-associated disease corresponding to its levelAllergology International, 2016
- Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant TuberculosisEBioMedicine, 2015
- The Site of Action of Oxazolidinone Antibiotics in Living Bacteria and in Human MitochondriaMolecular Cell, 2007
- Inhibition of Mammalian Mitochondrial Protein Synthesis by OxazolidinonesAntimicrobial Agents and Chemotherapy, 2006
- 1 H Nuclear Magnetic Resonance Study of Oxazolidinone Binding to Bacterial RibosomesAntimicrobial Agents and Chemotherapy, 2002